

6/14/04

06-17-2004

Form PTO-1595
(Rev. 10/02)
OMB No. 0651-0027 (exp. 6/30/2005)
Tab settings $\Rightarrow \Rightarrow \Rightarrow$ ∇ ∇

RECC



U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

102770146

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):
ICN Pharmaceuticals Inc.

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

2. Name and address of receiving party(ies)
Name: Ribapharm Inc.

Internal Address: _____

Street Address: 3300 Hyland Ave.

City: Costa Mesa State: CA Zip: 92626

Additional name(s) & address(es) attached? ☐ Yes ☒ No

3. Nature of conveyance:

☐ Assignment ☐ Merger

☐ Security Agreement ☐ Change of Name

☒ Other Contribution Agreement

Execution Date: 08/20/2002

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s) 10/136,932

B. Patent No.(s) _____

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Brown Raysman Millstein Felder & Steiner LLP

Internal Address: _____

Street Address: 900 Third Avenue

City: New York State: NY Zip: 10022

6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41).....\$ 40.00

☐ Enclosed

☒ Authorized to be charged to deposit account

8. Deposit account number:

02-4270 (docket 6319-642)

DO NOT USE THIS SPACE

9. Signature.

James P. Demers
Name of Person Signing

James P. Demers
Signature

June 10, 2004
Date

Total number of pages including cover sheet, attachments, and documents: 42

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

06/16/2004 GTON11 00000123 024270 10136932
01 FC:8021 40.00 DA

PATENT
REEL: 015454 FRAME: 0295

CONTRIBUTION AGREEMENT

This Contribution Agreement (the "Agreement") is made and entered into as of August 20, 2002 between ICN Pharmaceuticals, Inc., a Delaware corporation ("ICN") and Ribapharm Inc., a Delaware corporation ("Ribapharm").

WHEREAS, pursuant to duly adopted resolutions of the board of directors of ICN dated August 7, 2000 (the "August 2000 Resolutions") attached hereto as Schedule A, ICN contributed all of its right, title and interest in the Contributed Assets (as defined in the August 2000 Resolutions) including, without limitation, ICN's rights under the License and Supply Agreement by and between ICN and Schering-Plough Ltd. ("Schering") dated July 28, 1995 (the "S-P License");

WHEREAS, pursuant to duly adopted resolutions of the board of directors of ICN dated February 7, 2002 (the "February 2002 Resolutions") attached hereto as Schedule B, ICN (i) rescinded the contribution of the Costa Mesa Facility (as defined in the August 2000 Resolutions), (ii) contributed all of ICN's rights, title and interest in Hepavir B to Ribapharm and (iii) contributed all of ICN's rights, title and interest in IL-12 to Ribapharm;

WHEREAS, ICN, Schering and Ribapharm entered into a letter agreement dated March 8, 2002 (the "Consent") further outlining the rights and obligations of ICN, Schering and Ribapharm under the S-P License; and


WHEREAS, to facilitate the orderly recordation of transfer with the appropriate agencies, ICN and Ribapharm desire to set out with particularity a list of patents, trademarks, patent applications, trademark applications and any continuation, division, renewal, substitute, reissue or reexamination thereof contributed pursuant to the August 2000 Resolutions and February 2002 Resolutions (which list shall not be deemed to be a complete list of all patents and trademarks contributed by the August 2002 Resolutions and February 2002 Resolutions).

NOW, THEREFORE, the parties agree as follows:

1. ICN reaffirms (a) the contribution of Contributed Assets, except the Costa Mesa Facility contribution rescinded by the February 2002 Resolutions and (b) the contribution of Hepavir B and IL-12 made by the February 2002 Resolutions.
2. Ribapharm reaffirms its acceptance of (a) the contribution of Contributed Assets, except the Costa Mesa Facility contribution rescinded by the February 2002 Resolutions and (b) the contribution of Hepavir B and IL-12 made by the February 2002 Resolutions.
3. ICN and Ribapharm agree that the Contributed Assets include, without limitation, the patents, trademarks, patent applications, and any continuation, division, renewal, substitute, reissue or reexamination thereof set forth on Schedule C.

IN WITNESS WHEREOF, the undersigned have caused their duly authorized officers to execute this Agreement on the date first above written.

ICN PHARMACEUTICALS, INC.

By: 

Name: Harry A. Roosje

Title: Senior Vice President and Associate
General Counsel

RIBAPHARM INC.


By: 



Name: Roger D. Loomis, Jr.

Title: Senior Vice President and
General Counsel

State of California
County of Orange

Subscribed and sworn to before me this 20th day of August, 2002
by Roger D. Loomis, Jr. and Harry A. Roosje


Notary Public



SCHEDULE A

August 7, 2000

CERTIFICATE OF OFFICER

I, David C. Watt, a duly elected and qualified Officer of ICN Pharmaceuticals, Inc., a Delaware corporation (the "Company"), in accordance with applicable provisions of the Delaware General Corporation Law, hereby certify that the Board of Directors of the Company adopted the following resolutions at a meeting of the Board of Directors of the Company held on August 7, 2000, and that such resolutions have not been revoked and remain in full force and effect as of the date hereof.

WHEREAS, this Corporation caused Ribapharm Inc. ("Ribapharm") to be incorporated on April 14, 2000 and purchased 100 shares of the common stock of Ribapharm on May 1, 2000; and

WHEREAS, Ribapharm is a wholly-owned subsidiary of this Corporation; and

WHEREAS, this Board has determined that this Corporation should conduct all of its research and development activities in the United States (the "U.S. R&D Activities") through Ribapharm; and

WHEREAS, to accomplish this objective, this Corporation has decided to contribute to Ribapharm all of its assets related to the U.S. R&D Activities, as well as its rights under the License and Supply Agreement by and between ICN Pharmaceuticals, Inc. and Schering-Plough Ltd., dated July 28, 1995, as amended (the "S-P License Agreement") and related agreements, in each case subject to the qualifications set forth below (collectively, the "Contributed Assets"); and

WHEREAS, Ribapharm has received comments from the Securities and Exchange Commission (the "SEC") on its Registration Statement on Form S-1 (Registration No. 333-39350) with respect to the initial public offering of common stock of Ribapharm IPO (the "Ribapharm IPO") and it is advisable that this Corporation cause Ribapharm to file an amendment to its Registration Statement on Form S-1 in response to such comments and reflecting additional changes to the proposed structure of the Ribapharm IPO; and

WHEREAS, this Corporation has determined that in connection with the Ribapharm IPO, it is in the best interests of this Corporation to make an offer to purchase all of its outstanding 8 ¾% Senior Notes due 2008 (the "8 ¾% Senior Notes") and 9 ¼% Senior Notes (together with the 8 ¾% Senior Notes, the "Senior Notes") and to amend certain provisions of the indentures under which the Senior Notes were issued (the "Debt Offer and Consent"); and

WHEREAS, this Corporation has determined that it is desirable to seek bank or other financing to obtain the funds necessary to consummate the Debt Offer and Consent;

fny03\dameng\365936.1

NOW, THEREFORE, BE IT RESOLVED that this Corporation hereby contributes to Ribapharm all of its rights, title and interest in the Contributed Assets, including, without limitation, the following:

- (i) all chemical compounds related to the U.S. R&D Activities, including, without limitation, ribavirin (but excluding the Approved Indications for Ribavirin (as defined below), which are hereby being retained by this Corporation on a perpetual exclusive royalty-free basis), Levovirin, Viramidine, Tiazole (tiazofurin), Adenazole (8-Cl cAMP, Tocladesine), and all other nucleoside analog compounds, along with all related patents and patent applications, trademarks and trademark applications, goodwill, trade secrets, records, journals, data, equipment, materials and supplies (including, without limitation, the patents, trademarks, patent applications and trademark applications listed on Exhibit A and the goodwill related thereto, but excluding, without limitation, the patents, trademarks, patent applications and trademark applications listed on Exhibit B and the goodwill related thereto);
- (ii) the real property located at 3300 Hyland Avenue, Costa Mesa, CA 92626, including all buildings, fixtures in such buildings, and structures and other improvements situated thereon (the "Costa Mesa Facility");
- (iii) all furniture, equipment, materials, supplies, data, journals and records located at the Costa Mesa Facility and related to, or used in connection with, the U.S. R&D Activities (except for those assets listed on Exhibit C);
- (iv) the S-P License Agreement; and
- (v) all contracts between this Corporation and third parties relating to the U.S. R&D Activities or the S-P License Agreement, other than any contracts relating to the Approved Indications for Ribavirin;

provided, however, that to the extent the contribution of any asset hereunder requires the approval of the Office of Foreign Assets Control of the U.S. Department of the Treasury, such contribution shall not be effective unless and until such approval shall have been obtained;

provided, further, that the contribution of the S-P License Agreement and all contracts related thereto shall not be effective unless and until all requisite consents to the contribution of the S-P License Agreement and all such related contracts under the terms of the indentures relating to the Senior Notes have been obtained or are no longer required.

RESOLVED FURTHER, that, as used in the foregoing resolution, the term "Approved Indications for Ribavirin" shall mean all indications for ribavirin in a given jurisdiction to the

extent currently approved in that jurisdiction (but not in other jurisdictions for which that indication is not currently approved) as well as the potential indication for use of ribavirin in aerosol form in connection with treating RSV infections in bone marrow transplant patients (provided that the term "Approved Indications for Ribavirin" shall not include the use of ribavirin for the treatment of Hepatitis C (regardless of method of delivery)).

RESOLVED FURTHER, that the officers of this Corporation be, and each of them hereby is, authorized and empowered to cause Ribapharm to file with the SEC an amendment to its Registration Statement on Form S-1 substantially in the form presented to the directors for their consideration at this Board of Directors meeting, with any and all modifications or changes any such officer may deem necessary, desirable or advisable to be made consistent with the discussions that took place at this Board of Directors meeting.

RESOLVED FURTHER, that the officers of this Corporation be, and each of them hereby is, authorized, on behalf of this Corporation, to negotiate the terms of the Debt Offer and Consent and the terms of the bank or other debt financing necessary to finance the Debt Offer and Consent (the "Debt Refinancing"), subject to final approval of the terms of the Debt Offer and Consent and the Debt Refinancing by the Board of Directors.

RESOLVED FURTHER, that, in connection with the Debt Offer and Consent, the officers of this Corporation be, and each of them hereby is, authorized, in the name and on behalf of this Corporation, to hire such advisers and agents, including without limitation dealer managers, depositories, information agents and lawyers as any such officer may deem necessary or desirable, such hiring conclusively to evidence the due authorization thereof by this Corporation.

RESOLVED FURTHER, that the officers of this Corporation are authorized on behalf of this Corporation to enter into any agreements or execute any instruments useful or necessary to effect the intent of the foregoing resolutions.

WITNESS my hand this 8th day of April, 2002.



David C. Watt

Executive Vice President

Matters Moved to Subsidiary

Topic	Matter ID	Title	Matter Type	Status	Expiration Date	Patent Number
Subsidiary	189007-EP2	Subsidiary Human Use	Patent - Foreign	Pending		
Subsidiary	189007-Germany	Subsidiary Human Use	Patent - Foreign	Pending		
Subsidiary	189007-Hong Kong	Subsidiary Human Use	Patent - Foreign	Pending		
Subsidiary	189007-Japan	Subsidiary Human Use	Patent - Foreign	Issued	09/05/05	2005448
Subsidiary	182753-Canada (D1)	6-Cycle monophosphate Preparations	Patent - Foreign	Issued	08/27/12	1336073
Subsidiary	184003-Australia	Tiazole	Patent - Foreign	Issued	12/21/07	1548870
Subsidiary	184003-Austria	Tiazole	Patent - Foreign	Issued	12/14/01	54432
Subsidiary	184003-Belgium	Tiazole	Patent - Foreign	Issued	12/14/01	54482
Subsidiary	184003-Canada-D1	Tiazole	Patent - Foreign	Issued	10/02/01	1175421
Subsidiary	184003-Finland	Tiazole	Patent - Foreign	Issued	12/14/01	78373
Subsidiary	184003-France	Tiazole	Patent - Foreign	Issued	12/14/01	54432
Subsidiary	184003-Germany	Tiazole	Patent - Foreign	Issued	12/14/01	6317155.6-80
Subsidiary	184003-Great Britain	Tiazole	Patent - Foreign	Issued	12/14/01	54432
Subsidiary	184003-Israel	Tiazole	Patent - Foreign	Issued	12/14/01	84538
Subsidiary	184003-Italy	Tiazole	Patent - Foreign	Issued	12/14/01	54432
Subsidiary	184003-Japan	Tiazole	Patent - Foreign	Issued	07/02/02	1773305
Subsidiary	184003-Luxembourg	Tiazole	Patent - Foreign	Issued	12/14/01	54432
Subsidiary	184003-Netherlands	Tiazole	Patent - Foreign	Issued	12/14/01	54432
Subsidiary	184003-New Zealand	Tiazole	Patent - Foreign	Issued	12/14/01	190285
Subsidiary	184003-Norway	Tiazole	Patent - Foreign	Issued	12/14/01	150242
Subsidiary	184002-S. Africa	Tiazole	Patent - Foreign	Issued	12/10/01	810591
Subsidiary	185103-Argentina	Sulfazine	Patent - Foreign	Issued	19/02/00	247218
Subsidiary	185103-Austria	Sulfazine	Patent - Foreign	Issued	12/13/08	E 108791
Subsidiary	185103-Belgium	Sulfazine	Patent - Foreign	Issued	12/13/08	353 268
Subsidiary	185103-Canada	Sulfazine	Patent - Foreign	Issued	05/04/10	1317291
Subsidiary	185103-France	Sulfazine	Patent - Foreign	Issued	12/13/08	353 268
Subsidiary	185103-G. Britain	Sulfazine	Patent - Foreign	Issued	12/13/08	353 268
Subsidiary	185103-Germany	Sulfazine	Patent - Foreign	Issued	12/13/08	P3851054.5-08
Subsidiary	185103-Greece	Sulfazine	Patent - Foreign	Issued	12/13/08	100386
Subsidiary	185103-Holy	Sulfazine	Patent - Foreign	Issued	12/13/08	353 268
Subsidiary	185103-Japan	Sulfazine	Patent - Foreign	Issued	12/13/08	5004099
Subsidiary	185103-Korea (S)	Sulfazine	Patent - Foreign	Issued	02/11/13	137763
Subsidiary	185103-Luxembourg	Sulfazine	Patent - Foreign	Issued	12/13/08	353 268
Subsidiary	185103-Mexico	Sulfazine	Patent - Foreign	Issued	12/08/08	177733
Subsidiary	185103-Netherlands	Sulfazine	Patent - Foreign	Issued	12/13/08	353 268
Subsidiary	185103-New Zealand	Sulfazine	Patent - Foreign	Issued	12/13/08	not issued

17601

1 of 11

ICN Patents Schedules-02d (as of Aug 7, 2000).xls

Matters Moved to Subsidiary

Sulfazine	185703-Spain	Sulfazine	Patent - Foreign	Issued	Not found	2013379
Sulfazine	185703-Sweden	Sulfazine	Patent - Foreign	Issued	12/13/08	353 268
Sulfazine	185703-Switzerland	Sulfazine	Patent - Foreign	Issued	12/13/08	353 268
Sulfazine	185703-US	Sulfazine	Patent - US	Issued	08/20/08	6041542
Adenazide	185703 - ICN US5	Adenazide (8-Cl-cAMP)	Patent - US	Issued	05/10/15	5763419
Adenazide	185703 - (NH) US3	Adenazide (8-Cl-cAMP)	Patent - US	Issued	08/11/15	5782752
Adenazide	185703 - (NH) US4	Adenazide (8-Cl-cAMP)	Patent - US	Issued	05/01/12	5943016
Adenazide	185703 - (NH) US5	Adenazide (8-Cl-cAMP)	Patent - US	Issued	05/23/08	5902794
Ribavirin	198259-US	Viazole Derivative	Patent - US	Issued	11/02/08	4825000
Pyridylpyrimidine	198257-US	Substituted Pyrimido [5,4-Q] Pyrimidine ...	Patent - US	Issued	08/03/08	5041542
Sulfazine	198259-US1	Sulfazine, Sulfamide and Sulfonamide Purines and Processes of	Patent - US	Issued	11/22/08	5928036
Tiazofurin	198200-US	Treatment of malignant Tumors with 2-(8-D-Ribofuranosylthiazole-4-C	Patent - US	Issued	02/27/05	4880285
Adenazide	198202-US	8-Chloroadenine 3',5'-Cyclic Monophosphate Preparations	Patent - US	Issued	12/21/07	4881873
Oncazole	201069-Belgium	Oncazole	Patent - Foreign	Issued	08/15/03	163417
Oncazole	201069-Canada	Oncazole	Patent - Foreign	Issued	08/27/06	1254588
Oncazole	201069-Denmark	Oncazole	Patent - Foreign	Issued	02/14/04	158001
Oncazole	201069-France	Oncazole	Patent - Foreign	Issued	08/15/03	163417
Oncazole	201069-Germany	Oncazole	Patent - Foreign	Issued	08/18/03	163417
Oncazole	201069-Ireland	Oncazole	Patent - Foreign	Issued	07/27/03	55846
Oncazole	201069-Italy	Oncazole	Patent - Foreign	Issued	08/15/03	163417
Oncazole	201069-Japan	Oncazole	Patent - Foreign	Issued	08/18/03	1648637
Oncazole	201069-Luxembourg	Oncazole	Patent - Foreign	Issued	08/17/03	163417
Oncazole	201069-Netherlands	Oncazole	Patent - Foreign	Issued	08/18/03	163417
Oncazole	201069-Spain	Oncazole	Patent - Foreign	Issued	10/23/04	5250402
Oncazole	201069-Sweden	Oncazole	Patent - Foreign	Issued	08/18/03	163417
Oncazole	201069-Switzerland	Oncazole	Patent - Foreign	Issued	08/18/03	163417
Oncazole	201069-US	Oncazole	Patent - US	Issued	01/21/06	4781478
Oncazole	201069-Portugal-1	Oncazole	Patent - Foreign	Issued	02/04/06	76426
Selenazole	201062-Denmark	Selenazole compounds and method for production	Patent - Foreign	Issued	03/22/03	23093
Tiazofurin	201723-Australia	Tiazofurin & Ribavirin	Patent - Foreign	Pending		
Tiazofurin	201723-Brazil	Tiazofurin & Ribavirin	Patent - Foreign	Pending	05/16/14	678531
Tiazofurin	201723-EPO	Tiazofurin & Ribavirin	Patent - Foreign	Pending		
Tiazofurin	201723-Hong Kong	Tiazofurin & Ribavirin	Patent - Foreign	Pending		
Tiazofurin	201723-Japan	Tiazofurin & Ribavirin	Patent - Foreign	Pending		
Tiazofurin	201723-Korea (S)	Tiazofurin & Ribavirin	Patent - Foreign	Issued	09/03/00	2351407
Tiazofurin	201723-Mexico	Tiazofurin & Ribavirin	Patent - Foreign	Pending		

1/26/01

2 of 11

ICN Patents Schedules-02d (as of Aug 7, 2000).xls

Matters Moved to Subsidiary

Tazobactam	2010231-New Zealand	Tazobactam & Ribavirin	Patent - Foreign	Issued	11/03/14	266359
Tazobactam	2010233-Russian Fed	Tazobactam & Ribavirin	Patent - Foreign	Pending		
Tazobactam	2010233-US	Tazobactam & Ribavirin	Patent - US	Issued	05/18/13	3492437
Selenazole	2007165-US	Selenazole	Patent - US	Issued	06/22/04	4594414
Selenazole	2007165-US1	Selenazole	Patent - US	Issued	07/23/04	4594416
Selenazole	2007073-US	Selenazole	Patent - US	Issued	07/09/04	4618668
Sugar Mod Nuclo	213001-Australia	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	11/02/15	6903364
Sugar Mod Nuclo	213001-Canada	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Allowed		
Sugar Mod Nuclo	213001-China	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nuclo	213001-Czech	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nuclo	213001-EPO	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nuclo	213001-Hong Kong	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nuclo	213001-Hungary	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nuclo	213001-Japan	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nuclo	213001-Korea (S)	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nuclo	213001-Mexico	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nuclo	213001-Poland	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nuclo	213001-Russian Fed	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nuclo	213001-Slovakia	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nuclo	213001-Ukraine	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nuclo	213001-US1	Sugar Modified Nucleosides and Their Uses For Synt	Patent - US	Issued	11/02/14	5681940
Sugar Mod Nuclo	213001-US2	Sugar Modified Nucleosides and Their Uses For Synt	Patent - US	Issued	11/02/14	5712376
Sugar Mod Nuclo	213001-US3	Sugar Modified Nucleosides and Their Uses For Synt	Patent - US	Pending		
Sugar Mod Nuclo	213001-Yugoslavia (S)	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	06/23/16	9620113
AAVA	213002-Australia	Amino Acid Nucleic Acids	Patent - Foreign	Issued	11/02/15	680622
AAVA	213002-Canada	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AAVA	213002-China	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AAVA	213002-Czech	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AAVA	213002-EPO	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AAVA	213002-foreign gen	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AAVA	213002-Hungary	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AAVA	213002-Japan	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AAVA	213002-Korea (S)	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AAVA	213002-Mexico	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AAVA	213002-Poland	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AAVA	213002-Russian Fed	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AAVA	213002-Slovakia	Amino Acid Nucleic Acids	Patent - Foreign	Pending		

12/6/01

3 of 11

ICN Patents Schedules-02d (as of Aug 7, 2000).xls

NOV 22 '01 12:48

7146359136

PAGE 87

Matters Moved to Subsidiary

IANA	213002-Ukraine	Antisense Add Nucleic Acids	Patent - Foreign	Pending	5907135
IANA	213002-US3	Antisense Add Nucleic Acids	Patent - US	Issued	11/02/15
IANA	213002-Yugoslavia	Antisense Add Nucleic Acids	Patent - Foreign	Issued	04/29/17
CD28 10064	213003-Australia	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Issued	10/21/16
CD28 10064	213003-Canada	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending	
CD28 10064	213003-China	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending	
CD28 10064	213003-Czech	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending	
CD28 10064	213003-EPO	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending	
CD28 10064	213003-Hungary	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending	
CD28 10064	213003-Japan	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending	
CD28 10064	213003-Korea (S)	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Issued	08/09/17
CD28 10064	213003-Mexico	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending	
CD28 10064	213003-Poland	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending	
CD28 10064	213003-Russian Fed	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending	
CD28 10064	213003-Slovenia	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending	
CD28 10064	213003-Ukraine	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending	
CD28 10064	213003-US2	Methods and Compositions for Regulation of CD28 Expression	Patent - US	Issued	08/18/15
IL3 Antisense	213015-Australia	Inhibition of Tumor Growth by IL-3, IL-3 receptor	Patent - Foreign	Issued	5922568
IL3 Antisense	213015-Brazil/Hon	Inhibition of Tumor Growth by IL-3, IL-3 receptor	Patent - Foreign	Issued	11/16/16
IL3 Antisense	213015-Canada	Inhibition of Tumor Growth by IL-3, IL-3 receptor	Patent - Foreign	Pending	
IL3 Antisense	213015-China	Inhibition of Tumor Growth by IL-3, IL-3 receptor	Patent - Foreign	Pending	
IL3 Antisense	213015-Czech	Inhibition of Tumor Growth by IL-3, IL-3 receptor	Patent - Foreign	Pending	
IL3 Antisense	213015-EPO	Inhibition of Tumor Growth by IL-3, IL-3 receptor	Patent - Foreign	Pending	
IL3 Antisense	213015-Hong Kong	Inhibition of Tumor Growth by Antisense Oligonucleotides for ...	Patent - Foreign	Pending	
IL3 Antisense	213015-Hungary	Inhibition of Tumor Growth by IL-3, IL-3 receptor	Patent - Foreign	Pending	
IL3 Antisense	213015-Japan	Inhibition of Tumor Growth by IL-3, IL-3 receptor	Patent - Foreign	Pending	
IL3 Antisense	213015-Korea (S)	Inhibition of Tumor Growth by IL-3, IL-3 receptor	Patent - Foreign	Pending	
IL3 Antisense	213015-Macedonia	Inhibition of Tumor Growth by IL-3, IL-3 receptor	Patent - Foreign	Pending	
IL3 Antisense	213015-Mexico	Inhibition of Tumor Growth by IL-3, IL-3 receptor	Patent - Foreign	Pending	
IL3 Antisense	213015-Poland	Inhibition of Tumor Growth by IL-3, IL-3 receptor	Patent - Foreign	Pending	
IL3 Antisense	213015-Russian Fed	Inhibition of Tumor Growth by IL-3, IL-3 receptor	Patent - Foreign	Pending	
IL3 Antisense	213015-Slovak	Inhibition of Tumor Growth by IL-3, IL-3 receptor	Patent - Foreign	Pending	
IL3 Antisense	213015-Slovenia	Inhibition of Tumor Growth by IL-3, IL-3 receptor	Patent - Foreign	Issued	05/03/16
IL3 Antisense	213015-Ukraine	Inhibition of Tumor Growth by IL-3, IL-3 receptor	Patent - Foreign	Pending	19020122
IL3 Antisense	213015-US2	Inhibition of Tumor Growth by IL-3, IL-3 receptor	Patent - US	Issued	11/21/15
IL3 Antisense	213015-US4	Inhibition of Tumor Growth by IL-3, IL-3 receptor	Patent - US	Issued	02/05/17
CD44 Antisense	213027-Australia	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Issued	07/13/06

1/26/01

4 of 11

ICN Patents Schedules-02d (as of Aug 7, 2000).xls

Matters Moved to Subdiary

CD44 Antisense	213027-Canada	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213027-China	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213027-Czech	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213027-EPO	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213027-Hong Kong	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213027-Hungary	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213027-Israel	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213027-Japan	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213027-Korea (S)	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213027-Mexico	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213027-Poland	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213027-Russian Fed	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213027-Slovak	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213027-Ukraine	Control of CD44 Gene Expression for Therapeutic Use	Patent - US	Issued	08/11/15
CD44 Antisense	213027-US2	Control of CD44 Gene Expression for Therapeutic Use	Patent - US	Pending	5900250
CD44 Antisense	213027-US3	Control of CD44 Gene Expression for Therapeutic Use	Patent - US	Pending	
CD44 Antisense	213027-Yugoslavia(M)	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213027-Yugoslavia(S)	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
Glykoxides	213028-Australia	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Glykoxides	213028-Canada	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Glykoxides	213028-China	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Glykoxides	213028-Czech	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Glykoxides	213028-EPO	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Glykoxides	213028-foreign Genet	Carbohydrate Conjugated Bio-active Compounds	Patent - US	Pending	
Glykoxides	213028-Hungary	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Glykoxides	213028-Japan	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Glykoxides	213028-Korea (S)	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Glykoxides	213028-Mexico	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Glykoxides	213028-Poland	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Glykoxides	213028-Russia	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Issued	12/12/16
Glykoxides	213028-Slovak	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	RU 2141903
Glykoxides	213028-Ukraine	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Glykoxides	213028-US1	Carbohydrate Conjugated Bio-active Compounds	Patent - US	Issued	12/21/15
Glykoxides	213028-US2	Carbohydrate Conjugated Bio-active Compounds	Patent - US	Issued	5723589
Glykoxides	213028-US3	Carbohydrate Conjugated Bio-active Compounds	Patent - US	Issued	700542
Fluoridin	213102-Australia	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Fluoridin	213102-Brazil	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Fluoridin	213102-Canada	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	01/21/17
Fluoridin	213102-Canada	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	2346162

12/6/01

5 of 11

ICN Patents Schedules-02d (as of Aug 7, 2000).xls

Matters Moved to Subsidiary

Rhadin	213/102-China	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Rhadin	213/102-Czech	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Rhadin	213/102-EPO	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Rhadin	213/102-Hong Kong	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Rhadin	213/102-Hungary	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Rhadin	213/102-Israel	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Rhadin	213/102-Japan	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Rhadin	213/102-Korea	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Rhadin	213/102-Mexico	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Allowed	
Rhadin	213/102-New Zealand	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Rhadin	213/102-Norway	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Rhadin	213/102-Poland	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Rhadin	213/102-Russian Fed.	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Rhadin	213/102-Slovenia	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Rhadin	213/102-Ukraine	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Rhadin	213/102-US1	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - US	Issued	5/6/1997
Rhadin	213/102-US2	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - US	Issued	6/6/1997
Rhadin	213/102-US3	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - US	Allowed	
Rhadin	213/102-Yugo (Abroad)	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Rhadin	213/102-Yugo (Slovenia)	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	9/7/2018 9/7/2013
Taradin	213/133-US1	Manufacturing L-Ribocyclodextrins	Patent - US	Issued	6/5/2009 5/9/2006
Purine-L-Nucleoside	216/008-Argentina	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/008-Australia	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/008-Brazil/Hong Kong	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/008-Canada	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/008-China	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/008-Czech	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/008-EPO	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/008-Hong Kong	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/008-Hungary	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/008-India	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/008-Israel	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/008-Japan	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/008-Korea	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/008-Mexico/Canada	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	

12/8/01

6 of 11

ICN Patents Schedules-02d (as of Aug 7, 2000).xls

Matters Moved to Subsidiary

Purine-L-Nucleoside	216000-Mexico	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Purine-L-Nucleoside	216000-New Zealand	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Purine-L-Nucleoside	216000-Norway	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Purine-L-Nucleoside	216000-Poland	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Purine-L-Nucleoside	216000-Russia	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Purine-L-Nucleoside	216000-Serbia	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Purine-L-Nucleoside	216000-Slovenia	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Purine-L-Nucleoside	216000-Slovenia	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Purine-L-Nucleoside	216000-Ukraine	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Issued 10/19/17
Purine-L-Nucleoside	216000-US	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-Argentina	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - US	Pending
Levoritin 17261	216010-Australia	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-Brazil	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-Canada	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-China	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-Croatia	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-Czech	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-EPO	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-Hungary	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-Ireland	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-Japan	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-Korea	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-Mexico	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-New Zealand	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-Norway	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-Poland	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-Russian Fed.	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-Serbia	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-Slovenia	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-Slovenia	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-Ukraine	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending
Levoritin 17261	216010-US	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - US	Pending
Tazobactam	216011-Argentina	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	216011-Australia	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending

172601

7 of 11

ICN Patents Schedules-02d (as of Aug 7, 2000).xls

Matters Moved to Subsidiary

Tazobactam	2160011-Bosnia	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-Canada	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-China	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-Croatia	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-Czech	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-EPO	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-Hungary	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-Israel	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-Japan	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-Korea	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-Macedonia	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-Mexico	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-New Zealand	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-Norway	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-Poland	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-Russia	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-Serbia	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-Slovenia	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-Ukraine	Method of Producing Tazobactam and Other C-Nucleosides	Patent - Foreign	Pending
Tazobactam	2160011-US1	Method of Producing Tazobactam and Other C-Nucleosides	Patent - US	Allowed
Pyridoxaldehyde	2160012-Argentina	Multi-Valent Salts of Pyridoxaldehyde	Patent - Foreign	Pending
Pyridoxaldehyde	2160012-Australia	Multi-Valent Salts of Pyridoxaldehyde	Patent - Foreign	Pending
Pyridoxaldehyde	2160012-Bosnia	Multi-Valent Salts of Pyridoxaldehyde	Patent - Foreign	Pending
Pyridoxaldehyde	2160012-Brazil	Multi-Valent Salts of Pyridoxaldehyde	Patent - Foreign	Pending
Pyridoxaldehyde	2160012-Canada	Multi-Valent Salts of Pyridoxaldehyde	Patent - Foreign	Pending
Pyridoxaldehyde	2160012-China	Multi-Valent Salts of Pyridoxaldehyde	Patent - Foreign	Pending
Pyridoxaldehyde	2160012-Czech	Multi-Valent Salts of Pyridoxaldehyde	Patent - Foreign	Pending
Pyridoxaldehyde	2160012-EPO	Multi-Valent Salts of Pyridoxaldehyde	Patent - Foreign	Pending
Pyridoxaldehyde	2160012-Hungary	Multi-Valent Salts of Pyridoxaldehyde	Patent - Foreign	Pending
Pyridoxaldehyde	2160012-India	Multi-Valent Salts of Pyridoxaldehyde	Patent - Foreign	Pending
Pyridoxaldehyde	2160012-Israel	Multi-Valent Salts of Pyridoxaldehyde	Patent - Foreign	Pending
Pyridoxaldehyde	2160012-Japan	Multi-Valent Salts of Pyridoxaldehyde	Patent - Foreign	Pending
Pyridoxaldehyde	2160012-Korea	Multi-Valent Salts of Pyridoxaldehyde	Patent - Foreign	Pending
Pyridoxaldehyde	2160012-Macedonia	Multi-Valent Salts of Pyridoxaldehyde	Patent - Foreign	Pending
Pyridoxaldehyde	2160012-Mexico	Multi-Valent Salts of Pyridoxaldehyde	Patent - Foreign	Pending
Pyridoxaldehyde	2160012-New Zealand	Multi-Valent Salts of Pyridoxaldehyde	Patent - Foreign	Allowed
Pyridoxaldehyde	2160012-Norway	Multi-Valent Salts of Pyridoxaldehyde	Patent - Foreign	Pending

1/26/01

8 of 11

ICN Patents Schedules-02d (as of Aug 7, 2000).xls

Matters Moved to Subsidiary

Pyridoxamine	216012-Poland	Multivalent Salts of Pyridoxamine	Patent - Foreign	Pending	
Pyridoxamine	216012-Russia	Multivalent Salts of Pyridoxamine	Patent - Foreign	Pending	
Pyridoxamine	216012-Serbia	Multivalent Salts of Pyridoxamine	Patent - Foreign	Pending	
Pyridoxamine	216012-Slovenia	Multivalent Salts of Pyridoxamine	Patent - Foreign	Pending	
Pyridoxamine	216012-Slovenia	Multivalent Salts of Pyridoxamine	Patent - Foreign	Issued	20016
Pyridoxamine	216012-Ukraine	Multivalent Salts of Pyridoxamine	Patent - Foreign	Pending	
Pyridoxamine	216012-US1	Multivalent Salts of Pyridoxamine	Patent - US	Pending	
G-rich Oligo Apatite	216013-Australia	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-Bosnia	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-Brazil	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-Canada	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-China	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-Czech	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-EPO	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-Hungary	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-India	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-Israel	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-Japan	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-Korea	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-Macedonia	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-Mexico	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-New Zealand	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-Norway	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-Poland	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-Russia	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-Serbia	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-Slovenia	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-Slovenia	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-Ukraine	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - Foreign	Pending	
G-rich Oligo Apatite	216013-US1	G-rich Oligo Apatite and Methods of Modulating an Immune Response	Patent - US	Pending	
Ribavirin	216019-US1	Systemic Dosing of Ribavirin or Levovirin via Pulmonary Route	Patent - US	Pending	
Ribavirin	330.02-Australia	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Australia	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	1737884
Ribavirin	330.02-Bosnia	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	1742593
Ribavirin	330.02-Brazil	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Canada	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-China	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	

1/26/01

9 of 11

ICN Patents Schedules-02d (as of Aug 7, 2000) x.Bs

Matters Moved to Subsidiary

Ribavirin	330.02-Quotie	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Quach	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-EPO	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Hungary	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Unde	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Israel	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Japan	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Korea	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Mexico	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Mexico	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	5234526
Ribavirin	330.02-New Zealand	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Honey	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Poland	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Russia	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-S. Africa	Cytidine Related Treatments of Disease	Patent - Foreign	Allowed	
Ribavirin	330.02-Serbia	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Slovenia	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Slovenia	Cytidine Related Treatments of Disease	Patent - Foreign	Issued	01/13/18 9620003
Ribavirin	330.02-Ukraine	Cytidine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-US1	Cytidine Related Treatments of Disease	Patent - US	Pending	
Ribavirin	330.02-US6	Cytidine Related Treatments of Disease	Patent - US	Pending	
Ribavirin	330.12-PCT	Modulation of Immune Response by Ribavirin	Patent - PCT	Pending	
Ribavirin	330.12-US2	Modulation of Immune Response by Ribavirin	Patent - US	Pending	
Adenoside	330.14-PCT	Use of B-G-UMP for Prevention of Resistance	Patent - PCT	Pending	
Adenoside	330.14-PHO2	Use of B-G-UMP for Prevention of Resistance	Patent - Provisional	Pending	
Bicyclic Nucleoside	330.19-PCT	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - PCT	Pending	03/28/99
Bicyclic Nucleoside	330.19-US1	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - US	Pending	
Ribavirin	330.22-PHO	Stimulation of Neuronal Growth using Ribavirin and Levamisole	Patent - Provisional	Pending	
Acyclovir	330.26-PHO2	Acyclovir Analogues Having 2'-Methylenealkyl Chain	Patent - Provisional	Pending	
Ribavirin	330.34-US1	Multiple Agent Modulation of Chemokines	Patent - US	Pending	
Methylthio Nucleoside	330.37-PHO2	Nucleosides and Oligonucleotides Containing Methylthio and Spiro	Patent - Provisional	Pending	
Conformationally Constrained Nucleosides	330.39-US1	Conformationally Constrained Nucleosides	Patent - US	Pending	
Conformationally Constrained Nucleosides	330.39-US1	Conformationally Constrained Nucleosides and Oligonucleotides	Patent - US	Allowed	
Purine Nucleoside Analogs	330.46-PHO	Purine Nucleoside Analogs	Patent - Provisional	Pending	
Heterocyclic Aromatic Compounds and Uses Thereof	330.50-US1	Heterocyclic Aromatic Compounds and Uses Thereof	Patent - Provisional	Pending	
Pyridopyrimidinone	330.51-PHO	Pyridopyrimidinone and Pyridopyrimidinone Nucleosides	Patent - Provisional	Pending	
Vitamin	16776 330.53-PHO	Immunomodulator of Lower Toxicity than Ribavirin (17261)	Patent - Provisional	Pending	

1/26/01

10 of 11

ICN Patents Schedule-02d (as of Aug 7, 2000).xls

Matters Moved to Subsidiary

Macrocyclic L-Nucleosides with Type 1 Cytidine-Inhibiting Activity	338.64-PHO	Patent - Provisional	Pending
Use of Ribavirin and Levovirin as Targeted Immunomodulators	338.65-PHO	Patent - Provisional	Pending
Treatment of Viral Infections With Levovirin	338.66-US1	Patent - US	Pending
Phosphorylated Levovirin	338.68-PHO	Patent - Provisional	Pending
Artificial Cellulose	338.69-PHO	Patent - Provisional	Pending
Nucleoside Compounds and Uses Thereof	338.70-US1	Patent - Provisional	Pending

1/28/01

11 of 11

ICN Patents Schedules-02d (as of Aug 7, 2000).xls

NOV 82 '81 12:51

7146359136

PAGE.15

Exhibit A - Trademarks Being Transferred to Subsidiary

MARK	COUNTRY	TM No	APPL No
LEVOVIRIN	United States		75-850811
	European Community		
ADENAZOLE	United States		76-064924
	European Community		
VIRAMIDINE	United States		76-064998
	European Community		
THIAZOLE	United States		76-064923
	European Community		
SPAG	Benelux	466464	65264
	Canada	385911	620814
	Germany	1154833	V21070/10Wz
	Great Britain	1363233	1363233
	New Zealand	188829	188829
	Switzerland	367768	8025
	United States	1587615	776084
VIRAMID	China	293019	43337
	Dominican Republic	43456	
	Italy	604005	16,812 C/89
	Korea South		
	Mexico		553399/273965
	Norway	96749	113078
	Uruguay	230223	
VIRAZID	Great Britain	1307444	1307444
VIRAZIDE	Algeria	411025	272461
	Australia	A 465031	465031
	Austria	116040	3008/85
	Austria	411025	272461
	Benelux	331647	35570
	Benelux	411025	272461
	Chile	385572	
	Costarica	78339	
	Cuba		125742
	Dominican Republic	43455	
	Egypt	411025	272461
	El Salvador		

1 of 4

NOV 22 '81 12:51

7146359136

PAGE.16

PATENT
REEL: 015454 FRAME: 0312

Exhibit A - Trademarks Being Transferred to Subsidiary

MARK	COUNTRY	TM No.	APPL No.
VIRAZIDE	European Community		614735
	France	411025	272461
	Germany	411025	272461
	Greece	86602	86602
	Guatemala	57439	
	Honduras	49381	
	India	295985	295985
	International	411025	272461
	Italy	411025	272461
	Italy	643267	17800 C/89
	Japan	3351362	048212/95
	Lebanon	29902	
	Lebanon	54225	238/118645
	Liechtenstein	411025	272461
	Maroco	411025	272461
	Mexico	289569	
	Monaco	411025	272461
	New Zealand	175557	175557
	Portugal		234309
	Romania	411025	272461
	San Marino	411025	272461
	Spain	411025	272461
	Switzerland	272461	
	United States	75/335,054	
	Yugoslavia	411025	272461
VIRAZIL	Russia	73967	95752
VIRAZOL	Russia		95700129
	Russia	RU 147,470	RU 95700129
VIRAZOLE	Argentina	1314866	
	Aruba	9753	12249
	Australia	A 439400	429400
	Austria	157095	AM 4722/94
	Benelux	414501	54442
	Bermuda	8094	
	Bolivia	49,665-C	
	Brazil		817166360
	Canada	201567	358987
	China	293014	43333
	China		9900136709

Exhibit A - Trademarks Being Transferred to Subsidiary

MARK	COUNTRY	TN No	APPL No
VIRAZOLE	Colombia	8459	
	Costarica	45986	
	Curacao	9753	
	Czechoslovakia	166787	55739/NNFA
	Denmark	03.779/1973	4582/72
	Dominican Republic	21304	
	Ecuador	539	
	Egypt	100.874	
	Finland	102579	853490
	France	1323031	758710
	Germany	1131270/5	V19549/SWz
	Great Britain	1171757	1171757
	Greece	86803	86803
	Guatemala	50960	
	Honduras	45986	
	Hong Kong	442/1978	0107/1977
	India		480189
	Indonesia	208395	M/3004
	Ireland	145804	4871/90
	Italy	351751	3494877
	Japan	4109244	048211/95
	Jordan	4716	35159
	Korea South	214623	7835/90
	Korea South	207337	18079/89
	Kuwait	6890	7563
	Malaysia	85/04297	85/04297
	Malaysia	37813	94/05430
	Mexico	295722	
	New Zealand	161	160951
	Nicaragua	3,074 RPI	
	Norway	126421	85/3625
	Pakistan	87675	87675
	Panama	20,017	
		7378	
	Philippines	33738	26311
	Poland	53150	Z-71437
	Portugal	232265	232265
	RASA	4956	5065
	Salvador	187	
	Saudi Arabia	168/35	4328
	Singapore	S/4433/85	4433/85
	South Africa	85/7136	85/7136

3 of 4

Exhibit A - Trademarks Being Transferred to Subsidiary

MARK	COUNTRY	TM No	APPL No
VIRAZOLE	Spain	2058970	2058970
	Sweden	205801	85-06976
	Switzerland	342567	8151
	Taiwan	239658	72/43141
	Taiwan		88061506
	Thailand	TM 772	235590
	Trinidad	8049	
	United States	1829604	74/571024
	Venezuela	85,603-F	
	Yemen		2686
	Yugoslavia	30897	Z-761/85
	Zimbabwe	102/73	102/73

4 of 4

NOV 82 '81 12:53

7146359136

PAGE.19

PATENT
REEL: 015454 FRAME: 0315

Exhibit B

Matters Remaining in Patent

Topic	Matter ID	Title	Matter Type	Status	Expiration Date	Patent Number
Parasites	168204-US	5-Aminosalicylic Acid Trihydrochloride	Patent - US	Issued	07/28/00	4284222
Parasites	168205-US	5-Aminosalicylic Acid Trihydrochloride	Patent - US	Issued	07/28/00	4284247
Parasites	170148	Metabolite Dosage Forms	Patent - US	Issued	12/21/01	4454152
Parasites	172165-US	5-Aminosalicylic Acid	Patent - US	Issued	02/23/01	4929836
Parasites	173160-US	Pharmaceutical Benzothiazines	Patent - US	Issued	07/28/00	4279922
Parasites	182221-US	Pharmaceutical Antimicrobial	Patent - US	Issued	07/14/00	4903776
Parasites	204170-US	Quarantine Unit	Patent - US	Issued	03/28/04	4913901
Radiation Vial	210004-Benelux	Design for Vial	Patent - Foreign	Allowed	03/24/02	28337-00
Radiation Vial	210004-France	Design for Vial	Patent - Foreign	Allowed	03/27/02	8719415
Radiation Vial	210004-Germany	Design for Vial	Patent - Foreign	Issued		14 87 03 148.6
Radiation Vial	210004-Italy	Design for Vial	Patent - Foreign	Pending		
Radiation Vial	210004-Russian Fed	Design for Vial	Patent - Foreign	Issued	04/28/12	45030
Radiation Vial	210004-Spain	Design for Vial	Patent - Foreign	Issued	12/23/07	140049
Radiation Vial	210004-Sweden	Design for Vial	Patent - Foreign	Issued	04/28/02	83 047
Radiation Vial	210004-UK	Design for Vial	Patent - US	Issued	06/07/21	2061181
Radiation Vial	210004-DEB	Design for Vial	Patent - US	Issued	04/27/13	408857
Radiation Vial	210005-EPO	Packaging with Cartridge Tube	Patent - Foreign	Pending		
Radiation Vial	210005-US	Packaging with Cartridge Tube	Patent - US	Issued	07/21/10	9783632
UV Device	173159-DEB	Ultraviolet Lamp	Patent - US	Issued		DE3262187
	180050-US	Process for Introducing Vitrals B-12...	Patent - US	Issued	10/18/01	4432075
	174147-US	Compositions & Method for Simultaneous...	Patent - US	Issued	05/23/04	4672078
	174149-US	Direct Reading Automatic Pipette	Patent - US	Issued	10/31/03	4563907
	178131-US	Compositions and Methods for Multiple...	Patent - US	Issued	08/08/07	50016072
	188121-US	Medical Construction	Patent - US	Issued	08/22/12	5334352
	188208-US	Artisanal & Synthetic Medicines	Patent - US	Issued	02/27/09	4982476
	188201-US	T Cell Immunopotentiator	Patent - US	Issued	10/04/08	6860947
	188204-DEB	Infant Medical Head	Patent - US	Issued		DE322832
	198001-US	Scavenging Medical Head	Patent - US	Issued	07/28/00	4648714
	201001-US	Immunometric Assay Using Monoclonal A	Patent - US	Issued	08/04/00	4376110
	201002-US	Assay for the Free Portion of Substance...	Patent - US	Issued	08/28/00	4386143
	201003-US	Simultaneous Radioimmunoassay of Follicle...	Patent - US	Issued	02/23/01	4423154
	201004-US	Assay Process with Non-Binding Material...	Patent - US	Issued	03/23/01	4418151
	201005-US	Preparation of Samples for Vitamin B12	Patent - US	Issued	04/08/01	4451871
	201006-US	Immunometric Assay Using Monoclonal...	Patent - US	Issued	06/24/01	4466530
	201007-US	Immunoprecipitation Assay of Immuno...	Patent - US	Issued	08/19/05	4616559
	201008-US	9-(8-D-Ribitolamido) Purine-6-Carboxam...	Patent - US	Issued	08/28/00	4328338

1/26/01

1 of 2

ICN Patents Schedules-02d (as of Aug 7, 2000).xls

Matters Remaining in Patent

201/848-US	Data Collection and Sample Handling ...	Patent - US	Issued	07/21/03	5231304
201/850-US	Process for Treating Wet Fat Biological ...	Patent - US	Issued	08/19/03	4787200
201/851-US	Method for the Protection of 2'-Oxy ...	Patent - US	Issued	01/15/07	4789137
201/852-US	Fluid and Automatic Fluorescence ...	Patent - US	Issued	07/13/03	4638864
201/858-US	Pipette Tip Pickup Apparatus	Patent - US	Issued	11/12/11	8083780
201/783-US	Small Particle Aerosol Generator ...	Patent - US	Issued	03/07/06	4648911
213/958-US1	Improved Utilization of Virus	Patent - US	Issued	08/25/10	5786250
219/039-US	Two-Step Process for Coating Antibodies	Patent - US	Issued	08/28/12	5306000
530.88-PHO	IGs With Multiple Cds	Patent - Provisional	Pending		

1/28/01

2 of 2

ICN Patents Schedules-02d (as of Aug 7, 2000).xls

Exhibit C

1. All equipment forming ICN Pharmaceuticals, Inc.'s AS-400 mainframe computer system.
2. All equipment, materials, supplies, data, journals and records related to ICN Pharmaceuticals, Inc.'s dosimetry services operations.

- 5 -

Exp 03/14/80/03/17798J

NOV 02 '01 12:55

7146359136

PAGE.22

Resolutions of the
Board of Directors of
ICN Pharmaceuticals, Inc.

WHEREAS, on August 7, 2000, the Board of Directors of this Corporation previously adopted resolutions (the "August 2000 Resolutions") contributing to Ribapharm Inc. ("Ribapharm") all of the Corporation's rights, title and interest in the Contributed Assets (as defined in the August 2000 Resolutions), including, without limitation, the Costa Mesa Facility (as defined in the August 2000 Resolutions); furniture, equipment, materials, supplies, data, journals and records located at the Costa Mesa Facility and related to or used in connection with, U.S. research and development activities (the "Personal Property"); and chemical compounds related to U.S. research and development activities.

NOW THEREFORE BE IT RESOLVED, that the August 2000 Resolutions, to the extent such resolutions contributed to Ribapharm the Costa Mesa facility, are rescinded, it being understood that the contribution of all of the other Contributed Assets (including without limitation the Personal Property) remains in full force and effect;

RESOLVED FURTHER, that the officers of the Corporation be, and each of them hereby is, authorized, in the name and on behalf of the Corporation, to enter into a leasing arrangement with Ribapharm, with respect to a portion of the Costa Mesa facility, under terms they may deem necessary or advisable, such authorization to be conclusive upon the execution and delivery of the lease; and

RESOLVED FURTHER, that the Corporation hereby contributes to Ribapharm all of its rights, title and interest in ICN2001-3 (to be named Hepavir B), a nucleoside compound that the Corporation licensed from Metabasis Therapeutics, Inc. along with all related patents and patent applications, trademarks and trademark applications, goodwill, trade secrets, records, journals, data, equipment, materials and supplies;

RESOLVED FURTHER, that the Corporation hereby contributes to Ribapharm all of its rights, title and interest in IL-12, a compound that it may have received pursuant to an Exchange Agreement and a Transfer Agreement by and between Hoffman-La Roche and F. Hoffman-La Roche Ltd. and Ribapharm and ICN Puerto Rico, dated June 29, 2001, along with all related patents and patent applications, trademarks and trademark applications, goodwill, trade secrets, records, journals, data, equipment, materials and supplies; and

RESOLVED FURTHER, that the officers of this Corporation are authorized on behalf of this Corporation to enter into any agreements or execute any instruments useful or necessary to effect the intent of the foregoing resolutions.

SCHEDULE C

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.0002AR	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	P98 01 03953	Th1/Th2 (broad), Ribavirin
100848.0002AR2	Novel Nucleosides	Patent - Foreign	Pending	P 00 01 04639	Th1/Th2 (narrow), Ribavirin
100848.0002AU	Cytokine Related Treatments of Disease	Patent - Foreign	Issued	60238/98	Th1/Th2 (broad), Ribavirin
100848.0002AU2	Novel Nucleosides	Patent - Foreign	Allowed	48659/00	Th1/Th2 (narrow), Ribavirin
100848.0002BA	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	BAP 99398A	Th1/Th2 (broad), Ribavirin
100848.0002BA2	Novel Nucleosides	Patent - Foreign	Pending	BAP-00612A	Th1/Th2 (narrow), Ribavirin
100848.0002BR	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	P19807473-3	Th1/Th2 (broad), Ribavirin
100848.0002BR2	Novel Nucleosides	Patent - Foreign	Pending	P19816127-0	Th1/Th2 (narrow), Ribavirin
100848.0002CA	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	2278158	Th1/Th2 (broad), Ribavirin
100848.0002CA2	Novel Nucleosides	Patent - Foreign	Pending	00121912.X	Th1/Th2 (narrow), Ribavirin
100848.0002CN	Novel Nucleosides	Patent - Foreign	Pending	126807.4	Th1/Th2 (narrow), Ribavirin
100848.0002CN3	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	PV 2000-3804	Th1/Th2 (broad), Ribavirin
100848.0002CZ	Novel Nucleosides	Patent - Foreign	Pending	PV 2000-3805	Th1/Th2 (narrow), Ribavirin
100848.0002CZ3	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	98903474.9	Th1/Th2 (broad), Ribavirin
100848.0002EPO	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	00118252.6	Th1/Th2 (broad), Ribavirin
100848.0002EPO2	Novel Nucleosides	Patent - Foreign	Pending	00102855.0	Th1/Th2 (narrow), Ribavirin
100848.0002HK	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	01104385.4	Th1/Th2 (broad), Ribavirin
100848.0002HK2	Novel Nucleosides	Patent - Foreign	Allowed	P20000421A	Th1/Th2 (narrow), Ribavirin
100848.0002HR2	Cytokine Related Treatments of Disease	Patent - Foreign	Allowed	P20000423A	Th1/Th2 (broad), Ribavirin
100848.0002HR3	Novel Nucleosides	Patent - Foreign	Pending	P0001526	Th1/Th2 (narrow), Ribavirin
100848.0002HU	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	P00 02453	Th1/Th2 (broad), Ribavirin
100848.0002HU2	Novel Nucleosides	Patent - Foreign	Pending	137393	Th1/Th2 (narrow), Ribavirin
100848.0002IL2	Novel Nucleosides	Patent - Foreign	Pending	137392	Th1/Th2 (broad), Ribavirin
100848.0002IL3	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	1614/Ca/98	Th1/Th2 (broad), Ribavirin
100848.0002IN	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	646/CAL/2000	Th1/Th2 (narrow), Ribavirin
100848.0002IN2	Novel Nucleosides	Patent - Foreign	Pending	531245/98	Th1/Th2 (broad), Ribavirin
100848.0002JP	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	2001-155321	Th1/Th2 (narrow), Ribavirin
100848.0002JP2	Novel Nucleosides	Patent - Foreign	Pending	1999-7006393	Th1/Th2 (broad), Ribavirin
100848.0002KR	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	(PCT) 2001-	Th1/Th2 (narrow), Ribavirin
100848.0002KR2	Novel Nucleosides	Patent - Foreign	Pending	7004524	
100848.0002MK	Cytokine Related Treatments of Disease	Patent - Foreign	Issued	P-01/199	Th1/Th2 (broad), Ribavirin
100848.0002MK2	Novel Nucleosides	Patent - Foreign	Pending	P-20000059	Th1/Th2 (narrow), Ribavirin
100848.0002MX	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	996418	Th1/Th2 (broad), Ribavirin
100848.0002MX2	Novel Nucleosides	Patent - Foreign	Pending	09527	Th1/Th2 (narrow), Ribavirin
100848.0002NO	Novel Nucleosides	Patent - Foreign	Pending	2000 4327	Th1/Th2 (broad), Ribavirin
100848.0002NO3	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	2000 4329	Th1/Th2 (narrow), Ribavirin
100848.0002N2	Novel Nucleosides	Patent - Foreign	Issued	505531	Th1/Th2 (broad), Ribavirin
100848.0002N23	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	505530	Th1/Th2 (narrow), Ribavirin
100848.0002PL	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	P.336 579	Th1/Th2 (broad), Ribavirin
100848.0002RU2	Novel Nucleosides	Patent - Foreign	Pending	RU 2000122128	Th1/Th2 (narrow), Ribavirin
100848.0002RU3	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	RU 2000122127	Th1/Th2 (broad), Ribavirin

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.0002SB	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	P-615/98	Th1/Th2 (broad), Ribavirin
100848.0002SB2	Novel Nucleosides	Patent - Foreign	Pending	P-434/2000	Th1/Th2 (narrow), Ribavirin
100848.0002SI	Cytokine Related Treatments of Disease	Patent - Foreign	Issued	P-9820003	Th1/Th2 (broad), Ribavirin
100848.0002SK	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	PV 940-99	Th1/Th2 (broad), Ribavirin
100848.0002SK2	Novel Nucleosides	Patent - Foreign	Pending	PV 1487-2000	Th1/Th2 (narrow), Ribavirin
100848.0002UA2	Novel Nucleosides	Patent - Foreign	Pending	2000073981/I	Th1/Th2 (narrow), Ribavirin
100848.0002UA3	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	2000073980/I	Th1/Th2 (broad), Ribavirin
100848.0002US10	Cytokine Related Treatments of Disease	Patent - US	Pending	10/136745	Th1/Th2 (broad), Ribavirin
100848.0002US6	Cytokine Related Treatments of Disease	Patent - US	Allowed	09/467443	Th1/Th2 (broad), Ribavirin
100848.0002US7	Novel Nucleosides	Patent - US	Allowed	09/594647	Th1/Th2 (narrow), Ribavirin
100848.0002US8	Cytokine Related Treatments of Disease	Patent - US	Pending	09/594372	Th1/Th2 (broad), Ribavirin
100848.0002US9	Cytokine Related Treatments of Disease	Patent - US	Pending	09/595448	Th1/Th2 (broad), Ribavirin
100848.0002ZA	Cytokine Related Treatments of Disease	Patent - Foreign	Issued	986641	Th1/Th2 (broad), Ribavirin
100848.0012AR	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	668761	Ribavirin
100848.0012AU	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	24833/00	Ribavirin
100848.0012BA	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	BAP01842A	Ribavirin
100848.0012BR	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	P-19917090-6	Ribavirin
100848.0012CA	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	2357735	Ribavirin
100848.0012CN	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	99815897.6	Ribavirin
100848.0012CZ	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	PV 2001-2519	Ribavirin
100848.0012DE	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	299 24 200.5.	Ribavirin
100848.0012EPO	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	99968155.6	Ribavirin
100848.0012HK	Modulation of Immune Response by Ribavirin	Patent - Foreign	Allowed	2102923.6	Ribavirin
100848.0012HR	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	P20010496A	Ribavirin
100848.0012HU	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	P0200027	Ribavirin
100848.0012IL	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	144130	Ribavirin
100848.0012IN	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending		Ribavirin
100848.0012JP	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	2000-595690	Ribavirin
100848.0012KR	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	(PCT) 2001-7009609	Ribavirin
100848.0012MK	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	P/PCT20010/060	Ribavirin
100848.0012MX	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	PA/a/2001/007211	Ribavirin
100848.0012NO	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	2001 3529	Ribavirin
100848.0012NZ	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	512879	Ribavirin
100848.0012PL	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending		Ribavirin
100848.0012RU	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	RU 2001119056	Ribavirin
100848.0012SB	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	P-524/01	Ribavirin
100848.0012SI	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	P-9920099	Ribavirin
100848.0012SK	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	PV-2001-1009	Ribavirin
100848.0012UA	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	2001074909/M	Ribavirin
100848.0012US3	Modulation of Immune Response by Ribavirin	Patent - US	Pending	10/154189	Ribavirin

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.0012ZA	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	20015595	Ribavirin
100848.0019AR	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	1588903	Bicyclic Nucleosides
100848.0019AU	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	40100/99	Bicyclic Nucleosides
100848.0019BA	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	BAP00664A	Bicyclic Nucleosides
100848.0019BR	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	PI 9911596-4	Bicyclic Nucleosides
100848.0019CA	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	2333380	Bicyclic Nucleosides
100848.0019CN	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	99809057.3	Bicyclic Nucleosides
100848.0019CZ	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	PV 2000.4181	Bicyclic Nucleosides
100848.0019EPO	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	99923288.7	Bicyclic Nucleosides
100848.0019HK	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	1102939.9	Bicyclic Nucleosides
100848.0019HR	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	P20000751A	Bicyclic Nucleosides
100848.0019HU	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	P0102152	Bicyclic Nucleosides
100848.0019IL	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	139420	Bicyclic Nucleosides
100848.0019IN	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending		Bicyclic Nucleosides
100848.0019JP	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	2000-550331	Bicyclic Nucleosides
100848.0019KR	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	(PCT) 2000-7013335	Bicyclic Nucleosides
100848.0019MK	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending		Bicyclic Nucleosides
100848.0019MX	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	11473	Bicyclic Nucleosides
100848.0019NO	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	2000 5938	Bicyclic Nucleosides
100848.0019NZ	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	507913	Bicyclic Nucleosides
100848.0019PL	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	P 344303	Bicyclic Nucleosides
100848.0019RU	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	RU 200129663	Bicyclic Nucleosides
100848.0019SB	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	P-736/00	Bicyclic Nucleosides
100848.0019SI	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Issued	P-9920038	Bicyclic Nucleosides
100848.0019SK	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	PV 2000-1743	Bicyclic Nucleosides
100848.0019UA	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	2000116545/M	Bicyclic Nucleosides
100848.0019US1	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - US	Allowed	09/451708	Bicyclic Nucleosides
100848.0019ZA	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - US	Pending	1446636	Bicyclic Nucleosides
100848.0034US1	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Allowed	20006315	Bicyclic Nucleosides
100848.0038US1	Multiple Agent Modulation of Chemokines	Patent - US	Pending	09/561402	Bicyclic Nucleosides
100848.0039US1	Conformationally Constrained Nucleosides	Patent - US	Pending	09/569183	Ribavirin
100848.0048AR	Conformationally Locked Nucleosides and Oligonucleotides	Patent - US	Issued	09/309742	Conformationally Constrained Nucleosides
100848.0048AU	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	P02 01 00590	Nucleosides
100848.0048BA	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	70618/00	Pyrrolo-Pyrimidine 17739
100848.0048BR	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	BAP02995A	Pyrrolo-Pyrimidine 17739
100848.0048CA	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	PI0013642-5	Pyrrolo-Pyrimidine 17739
100848.0048CN	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending		Pyrrolo-Pyrimidine 17739
100848.0048CZ	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	PV 2002-727	Pyrrolo-Pyrimidine 17739

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.0048EP	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	959267.6	Pyrolo-Pyrimidine 17739
100848.0048HR	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	P20020163A	Pyrolo-Pyrimidine 17739
100848.0048HU	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending		Pyrolo-Pyrimidine 17739
100848.0048IL	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	147908	Pyrolo-Pyrimidine 17739
100848.0048IN	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	IN/PCT/2002/0022	Pyrolo-Pyrimidine 17739
100848.0048JP	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	8/DE	
100848.0048KR	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	2001-530332	Pyrolo-Pyrimidine 17739
		Patent - Foreign	Pending	(PCT) 2002-7002570	Pyrolo-Pyrimidine 17739
100848.0048MK	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending		Pyrolo-Pyrimidine 17739
100848.0048MX	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	PA/a/2002/001753	Pyrolo-Pyrimidine 17739
100848.0048NO	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	2002 0931	Pyrolo-Pyrimidine 17739
100848.0048NZ	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	516941	Pyrolo-Pyrimidine 17739
100848.0048PL	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending		Pyrolo-Pyrimidine 17739
100848.0048RU	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	2002103501	Pyrolo-Pyrimidine 17739
100848.0048SB	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	P-144/02	Pyrolo-Pyrimidine 17739
100848.0048SI	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	200020035	Pyrolo-Pyrimidine 17739
100848.0048SK	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	PV 177-2002	Pyrolo-Pyrimidine 17739
100848.0048UA	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	2002021355	Pyrolo-Pyrimidine 17739
100848.0048US1	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - US	Pending	10/048795	Pyrolo-Pyrimidine 17739
100848.0048ZA	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending		Pyrolo-Pyrimidine 17739
100848.0050AR	Heterocyclic Aromatic Compounds and Uses Thereof	Patent - Foreign	Pending	P02 01 02829	Viramidine/10776
100848.0050PCT	Heterocyclic Aromatic Compounds and Uses Thereof	Patent - PCT	Superseded	PCT/US01/05172	Viramidine/10776
100848.0050US1	Heterocyclic Aromatic Compounds and Uses Thereof	Patent - US	Allowed	09/565365	Viramidine/10776
100848.0050US2	Heterocyclic Aromatic Compounds and Uses Thereof	Patent - US	Pending	10/095665	Viramidine/10776
100848.0051PCT	Pyrido[2,3-d]Pyrimidine and Pyrimido[4,5-d]Pyrimidine Nucleosides	Patent - PCT	Pending	PCT/US01/41242	Pyrido-Pyrimidine 14686
100848.0056AR	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	P02 01 00253	Levovirin 17261
100848.0056AU	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	22816/01	Levovirin 17261
100848.0056BA	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	BAP021072A	Levovirin 17261
100848.0056BR	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	PI0016163-2	Levovirin 17261
100848.0056CA	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056CN	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056CZ	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	PV 2002-968	Levovirin 17261
100848.0056EP	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056HR	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	P20020486A	Levovirin 17261
100848.0056HU	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	Matter Type	Status	Serial Number	Ribapharm Client Ref.
100848.0056ID	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	W-00200201701	Levovirin 17261
100848.0056IL	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	148510	Levovirin 17261
100848.0056IN	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056JP	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056KR	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056MK	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056MX	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056MY	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	PI 20021021	Levovirin 17261
100848.0056NO	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	2002 2816	Levovirin 17261
100848.0056NZ	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	517633	Levovirin 17261
100848.0056PH	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056PL	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056RU	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056SB	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056SG	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	2002 01486-8	Levovirin 17261
100848.0056SI	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	P-200020046	Levovirin 17261
100848.0056SK	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	PV 625-2002	Levovirin 17261
100848.0056UA	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056US1	Treatment of Viral Infections With Levovirin	Patent - US	Pending	09/471513	Levovirin 17261
100848.0056US2	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056ZA	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	201 21 305.2	Levovirin 17261
100848.0070DE	Nucleoside Compounds and Uses Thereof	Patent - Foreign	Pending	1924208	Levovirin, Viramidine
100848.0070EPO1	Antiviral Pro-drug	Patent - Foreign	Pending		Viramidine
100848.0070EPO2	Nucleoside Compounds and Uses Thereof	Patent - Foreign	Pending	1920509.5	Levovirin, Viramidine
100848.0070PCT1	Antiviral Pro-drug	Patent - PCT	Pending	PCT/US01/08769	Pro-drugs, Levovirin, Viramidine
100848.0070PCT2	Nucleoside Compounds and Uses Thereof	Patent - PCT	Pending	PCT/US01/08713	Viramidine
100848.0070US1	Nucleoside Compounds and Uses Thereof	Patent - US	Pending	981287	Levovirin, Viramidine
100848.0071	RIBAPHARM	TMK - US	Allowed	76/071869	Levovirin, Viramidine
100848.0074US1	Rapid Generation of Diverse Nucleoside and Nucleotide Libraries	Patent - US	Pending	09/904248	Parallel Synthesis
100848.0087PCT	Improved Specificity in Treatment of Diseases	Patent - PCT	Pending	PCT/US00/33454	Viramidine
100848.0096	Pegylated Nucleosides	Patent - US	Not filed		
100848.0097AR	Methods and Compositions for Levovirin	Patent - Foreign	Pending	P02 01 00584	Levovirin 17261
100848.0097AU	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097BA	Methods and Compositions for Levovirin	Patent - Foreign	Pending	BAP021071A	Levovirin 17261
100848.0097BR	Methods and Compositions for Levovirin	Patent - Foreign	Pending	PI0016162-4	Levovirin 17261
100848.0097CA	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097CN	Methods and Compositions for Levovirin	Patent - Foreign	Pending	00817416.4	Levovirin 17261
100848.0097CZ	Methods and Compositions for Levovirin	Patent - Foreign	Pending	2002-2112	Levovirin 17261
100848.0097EP	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261

Rutan Matter ID	Title	Matter Type	Status	Serial Number	Ribapharm Client Ref.
100848.0097HR	Methods and Compositions for Levovirin	Patent - Foreign	Pending	P20020485A	Levovirin 17261
100848.0097HU	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097ID	Methods and Compositions for Levovirin	Patent - Foreign	Pending	W-00200201702	Levovirin 17261
100848.0097IL	Methods and Compositions for Levovirin	Patent - Foreign	Pending	148514	Levovirin 17261
100848.0097IN	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097JP	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097KR	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097MK	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097MX	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097MY	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097NO	Methods and Compositions for Levovirin	Patent - Foreign	Pending	2002 2969	Levovirin 17261
100848.0097NZ	Methods and Compositions for Levovirin	Patent - Foreign	Pending	517634	Levovirin 17261
100848.0097PH	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097PL	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097RU	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097SB	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097SG	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097SI	Methods and Compositions for Levovirin	Patent - Foreign	Pending	P-200020047	Levovirin 17261
100848.0097SK	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097UA	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097US	Methods and Compositions for Levovirin	Patent - US	Pending		Levovirin 17261
100848.0097ZA	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0100PCT	Nucleoside Analogs With Carboxamide Modified Bicyclic Base	Patent - PCT	Pending	PCT/US0140148	Viramidine
100848.0102PCT	Nucleoside Vaccine Adjuvants	Patent - PCT	Pending		Nucleoside Adjuvant
100848.0103AR	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	P02 01 02803	Pyrido-Pyrimidine 17739
100848.0103MY	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending		Pyrido-Pyrimidine 17739
100848.0103PCT	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - PCT	Pending	PCT/US02/06347	Pyrido-Pyrimidine 17739
100848.0103TW	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	91115523	Pyrido-Pyrimidine 17739
100848.0103US1	Pyrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - US	Pending	09/797549	Pyrido-Pyrimidine 17739
100848.0105PCT	Methods of Drug Delivery to Hepatocytes and Treatment of Flaviviridae Infections	Patent - PCT	Pending	PCT/US01/26057	Viramidine
100848.0106PRO2	Treatment of Gastroesophageal Reflux Disease	Patent - Provisional	Pending	60/377290	Photodynamic
100848.0112PCT	MCC Nucleoside Libraries and Compounds	Patent - PCT	Not filed		
100848.0112PRO	MCC Nucleoside Libraries and Compounds	Patent - Provisional	Pending	60/342337	
100848.0113PCT	Deazapurine Libraries and Compounds	Patent - PCT	Not filed		
100848.0113PRO	Deazapurine Libraries and Compounds	Patent - Provisional	Pending	60/342410	
100848.0114PCT	Substituted Cytidine Libraries and Compounds	Patent - PCT	Not filed		

PATENT

REEL: 015454 FRAME: 0325

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.0114PRO	Substituted Cytidine Libraries and Compounds	Patent - Provisional	Pending	60/342336	
100848.0115PCT	Unusual Nucleoside Libraries & Compounds for Antiviral & Anticancer Agents	Patent - PCT	Not filed		
100848.0115PRO	Modified Nucleoside Analog Libraries and Compounds	Patent - Provisional	Pending	60/342407	
100848.0116PCT	Substituted Purine Libraries and Compounds	Patent - PCT	Not filed		
100848.0116PRO	Substituted Purine Libraries and Compounds	Patent - Provisional	Pending	60/342441	
100848.0117PRO	Nucleoside Analogs Libraries and Compounds	Patent - Provisional	Pending	60/342452	
100848.0118PRO	MB6866 Invention	Patent - Provisional	Not filed		
100848.0126PRO	Direct and Specific Inhibitors for RNA/DNA in the De Novo Synthesis	Patent - Provisional	Pending	60/335309	
100848.0127PRO	Bivalent Inhibitors for HCV Polymerase	Patent - Provisional	Pending	60/346680	
100848.0130PRO	Yellow Laser for Prostrate Treatment	Patent - Provisional	Not filed		
100848.0131PRO	High-Load Controlled Release Of Nucleoside Drugs	Patent - Provisional	Pending	60/335099	
100848.0132PRO	Antiviral Combinations With Organ Specificity	Patent - Provisional	Pending	60/335096	
100848.0133PRO	Antiviral Combinations Using L-Nucleosides	Patent - Provisional	Pending	60/335097	
100848.0134PRO	Antiviral Combinations Including Cytokines	Patent - Provisional	Pending	60/335095	
100848.0136PRO	Neurological Effects of Ribavirin and RSV	Patent - Provisional	Pending	60/333311	Corp Devel
100848.0145PRO	Modified Nucleoside Library Compounds and Uses as Antiviral Agents	Patent - Provisional	Pending	60/350296	
100848.0146PRO	Tricyclic Nucleoside Libraries	Patent - Provisional	Pending	60/350249	
100848.0179PRO	Very Slow Time Release Interferon	Patent - Provisional	Not filed		
100848.0182PRO	Dinucleotide Compounds	Patent - Provisional	Pending	60/373735	
100848.0183PRO	Antiviral Compositions and Methods using IFN-gamma	Patent - Provisional	Pending	60/364429	
100848.0184US	RIBAPHARM X	Trademark - US	Not filed		
100848.0185PRO	Nucleoside Libraries, Synthetic Strategies, and Uses of Compounds Therein	Patent - Provisional	Pending	60/364681	

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.0186PRO	Phosphonate Nucleosides and Methods Therefor	Patent - Provisional	Pending	60/377024	Phosphonate Nucleosides
100848.0200PRO	Drug Combinations with PMEA and PMEA Prodrugs	Patent - Provisional	Not filed		
100848.0201PRO	Drug Combinations with IL-12	Patent - Provisional	Not filed		
100848.0204PRO	Sugar Modified Nucleosides as RNA-Polymerase Inhibitors	Patent - Provisional	Not filed		
100848.0205PRO	Protein Kinase Inhibitors	Patent - Provisional	Pending		Kinase Inhibitors
100848.0209PRO	Kinase Inhibitors	Patent - Provisional	Pending		Kinase Inhibitors
100848.169097AT	Ribavirin Human Use	Patent - Foreign	Pending		Ribavirin
100848.169097CH	Ribavirin Human Use	Patent - Foreign	Pending		Ribavirin
100848.169097DE	Ribavirin (Human Antiviral use)	Patent - Foreign	Issued	DD 261094	Ribavirin
100848.169097DE2	Ribavirin Human Use	Patent - Foreign	Pending	DE 3588232.8-08	Ribavirin
100848.169097EP2	Ribavirin Human Use	Patent - Foreign	Issued	94118300.6	Ribavirin
100848.169097FR	Ribavirin Human Use	Patent - Foreign	Pending		Ribavirin
100848.169097HK	Ribavirin Human Use	Patent - Foreign	Issued	98111842	Ribavirin
100848.169097IT	Ribavirin Human Use	Patent - Foreign	Pending		Ribavirin
100848.169097JP	Ribavirin Human Use	Patent - Foreign	Issued	122351/85	Ribavirin
100848.169097NL	Ribavirin Human Use	Patent - Foreign	Pending		Ribavirin
100848.169097OPP	Ribavirin Human Use European Opposition	Patent - Foreign	Pending		Ribavirin
100848.169097SE	Ribavirin Human Use	Patent - Foreign	Pending		Ribavirin
100848.169097UK	Ribavirin Human Use	Patent - Foreign	Pending		Ribavirin
100848.182262CD1	8-Chloroadenosine 3',5'-Cyclic monophosphate Preparations	Patent - Foreign	Issued	616661	Adenazole
100848.184002JP	Tiazole	Patent - Foreign	Issued	114152/82	Tiazofurin
100848.185103AR	Sulfasine	Patent - Foreign	Issued	312708	Sulfasine
100848.185103AT	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine
100848.185103BE	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine
100848.185103CA	Sulfasine	Patent - Foreign	Issued	585590	Sulfasine
100848.185103CH	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine
100848.185103DE	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine
100848.185103ES	Sulfasine	Patent - Foreign	Issued	88 03792	Sulfasine
100848.185103FR	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine
100848.185103GB	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine
100848.185103GR	Sulfasine	Patent - Foreign	Issued	880100833	Sulfasine
100848.185103IT	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine
100848.185103JP	Sulfasine	Patent - Foreign	Issued	500646/1989	Sulfasine
100848.185103KR	Sulfasine	Patent - Foreign	Issued	89-701531	Sulfasine
100848.185103LU	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.185103MX	Sulfasine	Patent - Foreign	Issued	14111	Sulfasine
100848.185103NL	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine
100848.185103NZ	Sulfasine	Patent - Foreign	Issued		Sulfasine
100848.185103SE	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine
100848.185103US	Sulfasine	Patent - US	Issued	275113	Sulfasine
100848.195183NS3	Adenazole (8-Cl-cAMP)	Patent - US	Issued	67420	Adenazole
100848.195183NS4	Adenazole (8-Cl-cAMP)	Patent - US	Issued	08/225097	Adenazole
100848.195183NS5	Adenazole (8-Cl-cAMP)	Patent - US	Issued	08/937020	Adenazole
100848.195183US5	Adenazole (8-Cl-cAMP)	Patent - US	Issued	08/438537	Adenazole
100848.198296US	Virazole Derivative	Patent - US	Issued	750026	Ribavirin
100848.198297US	Substituted Pyrimido [5,4-D] Pyrimidine . . .	Patent - US	Issued	1563056	Pyrido-Pyrimidine 14686
100848.198298US1	Sulfenamides, Sulfenamides and Sulfonamide Purines and Processes of Making	Patent - US	Issued	07/275113	Sulfasine
100848.198300US	Treatment of malignant Tumors with 2-(B-D-Ribofuranosylthiazole-4-Carboxamide & Related Compounds (Tiazofurin)	Patent - US	Issued	706084	Tiazofurin
100848.198302US	8-Chloroadenosine 3',5'-Cyclic Monophosphate Preparations	Patent - US	Issued	136407	Adenazole
100848.201069BE	Oncozole	Patent - Foreign	Issued	83304702	Oncozole
100848.201069CA	Oncozole	Patent - Foreign	Issued	433341	Oncozole
100848.201069CH	Oncozole	Patent - Foreign	Issued	83304702	Oncozole
100848.201069DE	Oncozole	Patent - Foreign	Issued	83304702	Oncozole
100848.201069DK	Oncozole	Patent - Foreign	Issued	663/84	Oncozole
100848.201069FR	Oncozole	Patent - Foreign	Issued	83304702	Oncozole
100848.201069IE	Oncozole	Patent - Foreign	Issued	1779/83	Oncozole
100848.201069IT	Oncozole	Patent - Foreign	Issued	83304702	Oncozole
100848.201069JP	Oncozole	Patent - Foreign	Issued	149739/83	Oncozole
100848.201069LU	Oncozole	Patent - Foreign	Issued	83304702	Oncozole
100848.201069NL	Oncozole	Patent - Foreign	Issued	83304702	Oncozole
100848.201069SE	Oncozole	Patent - Foreign	Issued	83304702	Oncozole
100848.201069US	Oncozole	Patent - Foreign	Issued	83304702	Oncozole
100848.201086PT1	Oncozole	Patent - US	Issued	06/821176	Oncozole
100848.201092DK	Selenazole compounds and method for production	Patent - Foreign	Issued		Oncozole
100848.201223AR	Tiazofurin & Ribavirin	Patent - Foreign	Issued	1299/83	Selenazole
100848.201223AT	Tiazofurin & Ribavirin	Patent - Foreign	Pending	328.234	Tiazofurin
100848.201223AU	Tiazofurin & Ribavirin	Patent - Foreign	Pending		Tiazofurin
100848.201223CA	Tiazofurin & Ribavirin	Patent - Foreign	Issued	67827/94	Tiazofurin
100848.201223CH	Tiazofurin & Ribavirin	Patent - Foreign	Pending	2161970	Tiazofurin
100848.201223DE	Tiazofurin & Ribavirin	Patent - Foreign	Pending		Tiazofurin
100848.201223EE	Tiazofurin & Ribavirin	Patent - Foreign	Pending		Tiazofurin
100848.201223ES	Tiazofurin & Ribavirin	Patent - Foreign	Issued	94916011.3-2107	Tiazofurin
100848.201223FR	Tiazofurin & Ribavirin	Patent - Foreign	Pending	2144703	Tiazofurin
100848.201223FR	Tiazofurin & Ribavirin	Patent - Foreign	Not filed		Tiazofurin

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.201223GB	Tiazofurin & Ribavirin	Patent - Foreign	Pending	GB 0707479	Tiazofurin
100848.201223HK	Tiazofurin & Ribavirin	Patent - Foreign	Issued	98112731.2	Tiazofurin
100848.201223JP	Tiazofurin & Ribavirin	Patent - Foreign	Issued	5235531/19994	Tiazofurin
100848.201223KR	Tiazofurin & Ribavirin	Patent - Foreign	Issued	95-705126	Tiazofurin
100848.201223MX	Tiazofurin & Ribavirin	Patent - Foreign	Pending	94 3666	Tiazofurin
100848.201223NL	Tiazofurin & Ribavirin	Patent - Foreign	Pending		Tiazofurin
100848.201223NZ	Tiazofurin & Ribavirin	Patent - Foreign	Issued	266359	Tiazofurin
100848.201223RU	Tiazofurin & Ribavirin	Patent - Foreign	Issued	95122466	Tiazofurin
100848.201223US	Tiazofurin & Ribavirin	Patent - US	Issued	08/065,348	Tiazofurin
100848.206165US	Selenazole	Patent - US	Issued	07/612267	Selenazole
100848.206166US1	Selenazole	Patent - US	Issued	07/612078	Selenazole
100848.207075US	Selenazole	Patent - US	Issued	07/629287	Selenazole
100848.213001AU	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	690394	Sugar Mod Nucleosides
100848.213001CA	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	2202280	Sugar Mod Nucleosides
100848.213001CA2	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending	2307311	Sugar Mod Nucleosides
100848.213001CN	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending	95196962.5	Sugar Mod Nucleosides
100848.213001CZ	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending	PV 1997-1291	Sugar Mod Nucleosides
100848.213001E	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending	95939864.5-2110	Sugar Mod Nucleosides
100848.213001HK	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending	98109044	Sugar Mod Nucleosides
100848.213001HU	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending	P9702445	Sugar Mod Nucleosides
100848.213001JP	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending	515519/96	Sugar Mod Nucleosides
100848.213001KR	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	97-702924	Sugar Mod Nucleosides
100848.213001MX	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	97 3192	Sugar Mod Nucleosides
100848.213001PL	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending	P 319944	Sugar Mod Nucleosides
100848.213001RU	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	PCT/US95/14	Sugar Mod Nucleosides
100848.213001SK	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending	PV 548-97	Sugar Mod Nucleosides
100848.213001UA	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	97041994/M	Sugar Mod Nucleosides

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.213001US1	Sugar Modified Nucleosides and Their Uses For Synt	Patent - US	Issued	1448401	Sugar Mod Nucleosides
100848.213001US2	Sugar Modified Nucleosides and Their Uses For Synt	Patent - US	Issued	08/552363	Sugar Mod Nucleosides
100848.213001US3	Sugar Modified Nucleosides and Their Uses For Synt	Patent - US	Issued	08/766991	Sugar Mod Nucleosides
100848.213001US4	Sugar Modified Nucleosides and Oligonucleotides	Patent - US	Pending	09/697545	Sugar Mod Nucleosides
100848.213001YU	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	P-9520113	Sugar Mod Nucleosides
100848.213002AU	Amino Acid Nucleic Acids	Patent - Foreign	Issued	35005	AANA
100848.213002CA	Amino Acid Nucleic Acids	Patent - Foreign	Pending	2202274	AANA
100848.213002CN	Amino Acid Nucleic Acids	Patent - Foreign	Pending	95196989.7	AANA
				(PCT/US95	
100848.213002CZ	Amino Acid Nucleic Acids	Patent - Foreign	Issued	PV6620/97	AANA
100848.213002E	Amino Acid Nucleic Acids	Patent - Foreign	Pending	95940671.1	AANA
100848.213002HU	Amino Acid Nucleic Acids	Patent - Foreign	Issued	P9702053	AANA
100848.213002JP	Amino Acid Nucleic Acids	Patent - Foreign	Pending	515518/96	AANA
100848.213002KR	Amino Acid Nucleic Acids	Patent - Foreign	Pending	97-702925	AANA
100848.213002MX	Amino Acid Nucleic Acids	Patent - Foreign	Pending	973188	AANA
100848.213002PL	Amino Acid Nucleic Acids	Patent - Foreign	Pending	P320 084	AANA
100848.213002RU	Amino Acid Nucleic Acids	Patent - Foreign	Issued	RU 97108680	AANA
100848.213002SK	Amino Acid Nucleic Acids	Patent - Foreign	Issued	PUV 165-97	AANA
100848.213002UA	Amino Acid Nucleic Acids	Patent - Foreign	Allowed	97041995/M	AANA
100848.213002US3	Amino Acid Nucleic Acids	Patent - Foreign	Issued	08/551947	AANA
100848.213002YU	Amino Acid Nucleic Acids	Patent - Foreign	Issued	P-9520112	AANA
100848.213003AU	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Issued	52958/96	CD28 16064
100848.213003KR	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Issued	97-705496	CD28 16064
100848.213003US2	Methods and Compositions for Regulation of CD28 Expression	Patent - US	Issued	08/529878	CD28 16064
100848.213015AU	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Issued	10531/97	IL8 Antisense
100848.213015RU	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Issued	EA 199800391/26	IL8 Antisense
100848.213015SI	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Issued	P-9620122	IL8 Antisense
100848.213015US2	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - US	Issued	08/796031	IL8 Antisense
100848.213015US4	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - US	Issued	09/055913	IL8 Antisense
100848.213027AU	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Issued	66866/96	CD44 Antisense
100848.213027US2	Control of CD44 Gene Expression for Therapeutic Use	Patent - US	Issued	08/514542	CD44 Antisense
100848.213028E	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	96944345.6-2110	Glinkosides
100848.213028JP	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	523710/97	Glinkosides

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	Matter Type	Status	Serial Number	Ribapharm Client Ref.
100848.213028RU	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Issued	RU 97115878	Glinkosides
100848.213028US1	Carbohydrate Conjugated Bio-active Compounds	Patent - US	Issued	08/576817	Glinkosides
100848.213102AU	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	17478/97	Ribavirin
100848.213102BA	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	Up-4270/98	Ribavirin
100848.213102BR	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	PI 9707154-4	Ribavirin
100848.213102CA	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	2246162	Ribavirin
100848.213102CN	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	97191776	Ribavirin
100848.213102CZ	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	PV 2329-98	Ribavirin
100848.213102E	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	97904765.1	Ribavirin
100848.213102E2	Modulation of TH1/TH2 Cytokine Expression by Ribavirin	Patent - Foreign	Pending	1112901.2	Ribavirin
100848.213102E3	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	02009781.2	Ribavirin
100848.213102HK	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	99100284.7	Ribavirin
100848.213102HU	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	P9900681	Ribavirin
100848.213102IL	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	125088	Ribavirin
100848.213102JP	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	526907/97	Ribavirin
100848.213102KR	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	PCT/US98/05645	Ribavirin
100848.213102MK	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Allowed	P-067/98	Ribavirin
100848.213102MX	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	985963	Ribavirin
100848.213102NO	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	98.3372	Ribavirin
100848.213102NZ	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	330784	Ribavirin
100848.213102PL	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	P.328 003	Ribavirin
100848.213102RU	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Allowed	RU 98115594/14	Ribavirin

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	Matter Type	Status	Serial Number	Ribapharm Client Ref.
100848.213102SK	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	PV 1004-98	Ribavirin
100848.213102UA	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Allowed	98073815/M	Ribavirin
100848.213102US1	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - US	Issued	08/603106	Ribavirin
100848.213102US2	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - US	Issued	09/097450	Ribavirin
100848.213102US3	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - US	Issued	09/156646	Ribavirin
100848.213102US4	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - US	Pending	09/624855	Ribavirin
100848.213102US5	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - US	Pending	10/094032	Ribavirin
100848.213102YU	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	P-9720013	Ribavirin
100848.213133US1	Manufacturing L-Ribo-C-nucleosides	Patent - US	Issued	08/603106	Tiazofurin
100848.216009AR	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P99 01 01930	Purine-L-Nucleosides
100848.216009AR2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P 01 01 01046	Purine-L-Nucleosides
100848.216009AU	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Issued	48999/97	Purine-L-Nucleosides
100848.216009AU2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	45137/00	Purine-L-Nucleosides
100848.216009BA	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	BAP99418A	Purine-L-Nucleosides
100848.216009BA	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	BAP-00613A	Purine-L-Nucleosides
100848.216009BR	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	PI 9714349-9	Purine-L-Nucleosides
100848.216009BR2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending		Purine-L-Nucleosides
100848.216009CA	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	2323791	Purine-L-Nucleosides
100848.216009CA2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	2266889	Purine-L-Nucleosides
100848.216009CN2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	00122459.X	Purine-L-Nucleosides
100848.216009CN3	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	00122458.1	Purine-L-Nucleosides
100848.216009CZ2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	PV 1999-1267	Purine-L-Nucleosides
100848.216009CZ3	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	PV 2000-2532	Purine-L-Nucleosides
100848.216009E	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	97911684.5	Purine-L-Nucleosides
100848.216009E(2)	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	00118428.2110	Purine-L-Nucleosides
100848.216009HK	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	100589.7	Purine-L-Nucleosides
100848.216009HK2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	01103600.5	Purine-L-Nucleosides
100848.216009HR2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Allowed	P20000420A	Purine-L-Nucleosides
100848.216009HR3	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Allowed	P20000422A	Purine-L-Nucleosides
100848.216009HU	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P0001186	Purine-L-Nucleosides
100848.216009HU2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P00 02452	Purine-L-Nucleosides
100848.216009IL2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	137390	Purine-L-Nucleosides
100848.216009IL3	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	137391	Purine-L-Nucleosides
100848.216009IN	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	335/Cal/99	Purine-L-Nucleosides

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.216009JP	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	518475/98	Purine-L-Nucleosides
100848.216009JP2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	2001-110027	Purine-L-Nucleosides
100848.216009KR	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	1999-7003276	Purine-L-Nucleosides
100848.216009KR2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	(PCT) 2000-7014248	Purine-L-Nucleosides
100848.216009MK	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P-30/99	Purine-L-Nucleosides
100848.216009MK2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P-20000060	Purine-L-Nucleosides
100848.216009MX	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	993285	Purine-L-Nucleosides
100848.216009MX2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	009526	Purine-L-Nucleosides
100848.216009NO2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	2000 4326	Purine-L-Nucleosides
100848.216009NO3	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	2000 4328	Purine-L-Nucleosides
100848.216009NZ2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	505554	Purine-L-Nucleosides
100848.216009NZ3	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Allowed	505553	Purine-L-Nucleosides
100848.216009PL	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P-332694	Purine-L-Nucleosides
100848.216009RU	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Allowed	RU 99109467	Purine-L-Nucleosides
100848.216009RU2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	RU-2000122129	Purine-L-Nucleosides
100848.216009SB	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P-188/99	Purine-L-Nucleosides
100848.216009SB2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P-435/2000	Purine-L-Nucleosides
100848.216009SI	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Issued	P-9720067	Purine-L-Nucleosides
100848.216009SK	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	PV 481-99	Purine-L-Nucleosides
100848.216009SK2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	PV 1158-2000	Purine-L-Nucleosides
100848.216009UA2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	2000073982/1	Purine-L-Nucleosides
100848.216009UA3	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	2000073983/1	Purine-L-Nucleosides
100848.216009US3	Purine L-Nucleosides (DIV-narrow)	Patent - US	Allowed	09/594271	Purine-L-Nucleosides
100848.216009US4	Purine L-Nucleosides (DIV-broad)	Patent - US	Pending	09/595364	Purine-L-Nucleosides
100848.216009US5	Purine L-Nucleosides (DIV-narrow)	Patent - US	Pending	10/058855	Purine-L-Nucleosides
100848.216010AR	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	11324	Levovirin 17261
100848.216010AU	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Issued	49867/97	Levovirin 17261
100848.216010BA	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	Up-2178/99	Levovirin 17261
100848.216010BR	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	PI 9712527-0	Levovirin 17261
100848.216010CA	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	2267279	Levovirin 17261
100848.216010CN	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	97180619.5	Levovirin 17261
100848.216010CZ	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	PV 1206-99	Levovirin 17261
100848.216010E	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	97912762.8	Levovirin 17261

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.216010E2	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	1108303.7	Levovirin 17261
100848.216010E3	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	2007191.6	Levovirin 17261
100848.216010HK	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	106873.9	Levovirin 17261
100848.216010HK2	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	1107955.7	Levovirin 17261
100848.216010HR	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Allowed	P990147A	Levovirin 17261
100848.216010HU	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P0001107	Levovirin 17261
100848.216010IL	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	129126	Levovirin 17261
100848.216010IN	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	336/Cal/99	Levovirin 17261
100848.216010JP	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	518612/98	Levovirin 17261
100848.216010KR	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	(PCT) 1999-7003326	Levovirin 17261
100848.216010MK	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P-31/99	Levovirin 17261
100848.216010MX	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	993434	Levovirin 17261
100848.216010NO	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	1999 1785	Levovirin 17261
100848.216010NZ	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Issued	334915	Levovirin 17261
100848.216010PL	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P.333419	Levovirin 17261
100848.216010RU	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Allowed	RU 99109459	Levovirin 17261
100848.216010RU2	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	RU 2001132536	Levovirin 17261
100848.216010SB	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P-187/99	Levovirin 17261
100848.216010SI	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Issued	P-9720065	Levovirin 17261
100848.216010SK	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	PV 471-99	Levovirin 17261
100848.216010UA	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	99042175	Levovirin 17261

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.216010US1	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - US	Issued	09/291903	Levovirin 17261
100848.216010US2	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - US	Allowed	09/633493	Levovirin 17261
100848.216010US3	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - US	Pending	09/969355	Levovirin 17261
100848.216010US4	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - US	Pending	10/120101	Levovirin 17261
100848.216011AR	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	1501149	Tiazofurin
100848.216011AU	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Issued	82688/98	Tiazofurin
100848.216011BA	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	BAP99523A	Tiazofurin
100848.216011BR	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	PI 9810364-4	Tiazofurin
100848.216011CA	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	2290364	Tiazofurin
100848.216011CN	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	98806383.2	Tiazofurin
100848.216011CZ	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	PV 4631-99	Tiazofurin
100848.216011E	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	98932904	Tiazofurin
100848.216011HR	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	P990365A	Tiazofurin
100848.216011HU	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	P0002389	Tiazofurin
100848.216011IL	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	132737	Tiazofurin
100848.216011JP	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	505797/99	Tiazofurin
100848.216011KR	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	PCT/US701255	Tiazofurin
100848.216011MK	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	P-100/99	Tiazofurin
100848.216011MX	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	9911409	Tiazofurin
100848.216011NO	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	1999 6467	Tiazofurin
100848.216011NZ	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Issued	500831	Tiazofurin

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.216011PL	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	P.337716	Tiazofurin
100848.216011RU	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	RU 2000100307	Tiazofurin
100848.216011SB	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	P-670/99	Tiazofurin
100848.216011SI	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Issued	P-9820052	Tiazofurin
100848.216011SK	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	PV 1723-99	Tiazofurin
100848.216011UA	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	99126884	Tiazofurin
100848.216011US1	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - US	Pending	09/445713	Tiazofurin
100848.216012AU	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Issued	62367/98	Pyridostigmine
100848.216012NZ	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Issued	335419	Pyridostigmine
100848.216012SI	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Issued	P9720075	Pyridostigmine
100848.216012US1	Multi-Valent Salts of Pyridostigmine	Patent - US	Issued	09/308723	Pyridostigmine
100848.216013E	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending	97953460.9	G-rich Oligo Aptamers
100848.216013JP	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending	530233/98	G-rich Oligo Aptamers
100848.216013SI	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Issued	P-9720081	G-rich Oligo Aptamers
100848.216013US1	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - US	Pending	09/331204	G-rich Oligo Aptamers

PATENT

REEL: 015454 FRAME: 0336

RECORDED: 06/14/2004